Martina Leoni Archivi

Ipovitaminosi D e sindrome metabolica

Martina Leoni^1*– , Marco Infante ^1,^2,3,4,*– , Raffaele Infante ⁴– , Massimiliano Caprio ^5,6– , Andrea Fabbri¹ –

1 – UOC transmurale di Endocrinologia & Diabetes Research Institute Federation (DRIF), Dipartimento di Medicina dei Sistemi, Ospedali CTO A. Alesini & S.Eugenio, ASL Roma 2, Università di Roma Tor Vergata (Roma, Italia)

2 – UniCamillus, Saint Camillus International University of Health Sciences (Roma, Italia)

3 – Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN) (Roma, Italia)

4 – Cardio Endocrino Metabolica (CEM) – Endocrine and Cardiometabolic Center (Salerno, Italia)

5 – Dipartimento di Scienze Umane e Promozione della Qualità della Vita, Università San Raffaele Roma (Roma, Italia)

6 – Laboratorio di Endocrinologia Cardiovascolare, IRCCS San Raffaele Roma (Roma, Italia)

*Martina Leoni e Marco Infante hanno contribuito in egual misura alla stesura del presente articolo.

Autore di riferimento: Marco Infante

marco.infante@unicamillus.org

DOI: 10.53146/lriog1202162

Abstract

Metabolic syndrome is a complex disorder characterized by the co-occurrence of several known cardiovascular risk factors, including obesity, insulin resistance, atherogenic dyslipidemia and hypertension. As such, metabolic syndrome is associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. Of note, metabolic syndrome is defined by the presence of at least three of the following conditions: abdominal obesity (or central obesity), high blood pressure (≥130/≥85 mmHg), abnormal fasting plasma glucose (≥100 mg/dL), elevated serum triglycerides (≥150 mg/dL) and low high-density lipoprotein (HDL)-cholesterol level (

Keywords: metabolic syndrome; obesity; vitamin D deficiency; insulin resistance; type 2 diabetes mellitus; cardiometabolic risk.

Presente in LRIOG Nr.1 – 2022

e-ISSN: 1824-0283

Scarica il pdf